TDMS Study 96020-01 Pathology Tables
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:51:53 FINAL #1 Facility: Battelle Columbus Laboratory Chemical CAS #: TEFBINARYMIX Lock Date: 03/27/02 Cage Range: All Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice 25020 Natural Death 25021 Terminal Sacrifice Removal Date Range: All Treatment Groups: Include 001 0 NG / 0 UG Include 002 10 NG / 10 UG Include 003 100 NG /100 UG Include 005 300 NG /300 UG Include 007 1000 NG/1000 UG a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:51:53 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 98 86 98 98 98 Early Deaths Moribund Sacrifice 22 19 24 19 20 Natural Death 8 12 6 10 7 Dosing Accident 1 1 1 2 Survivors Terminal Sacrifice 22 21 22 24 24 Animals Examined Microscopically 53 53 53 53 53 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Intestine Large, Colon (53) (53) (53) (52) (49) Intestine Large, Rectum (53) (53) (53) (53) (50) Schwannoma Malignant, Metastatic, Vagina 1 (2%) 1 (2%) Intestine Large, Cecum (53) (53) (53) (52) (49) Intestine Small, Duodenum (53) (53) (52) (52) (50) Leiomyoma 2 (4%) Intestine Small, Jejunum (53) (53) (52) (52) (49) Leiomyosarcoma 1 (2%) Intestine Small, Ileum (53) (53) (52) (52) (49) Liver (53) (53) (52) (52) (51) Cholangiocarcinoma 4 (8%) 9 (18%) Cholangiocarcinoma, Multiple 1 (2%) 5 (10%) 21 (41%) Hemangioma 1 (2%) Hepatocellular Carcinoma 2 (4%) Hepatocellular Adenoma 3 (6%) 5 (10%) 11 (22%) Hepatocellular Adenoma, Multiple 16 (31%) Hepatocholangioma 2 (4%) 5 (10%) Hepatocholangioma, Multiple 1 (2%) Mesentery (47) (47) (46) (47) (42) Nephroblastoma, Metastatic, Kidney 1 (2%) Oral Mucosa (12) (11) (25) (30) (36) Gingival, Squamous Cell Carcinoma 2 (8%) 5 (17%) 8 (22%) Gingival, Squamous Cell Carcinoma, Multiple 1 (3%) Pancreas (53) (53) (52) (52) (50) Acinus, Adenoma 1 (2%) 1 (2%) 3 (6%) 1 (2%) Acinus, Carcinoma 1 (2%) 1 (2%) Salivary Glands (53) (51) (52) (50) (52) Stomach, Forestomach (53) (53) (52) (52) (51) Page 2 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:51:53 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Stomach, Glandular (53) (53) (52) (52) (51) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Blood Vessel (53) (53) (52) (53) (52) Heart (53) (52) (52) (53) (52) Fibrosarcoma, Metastatic, Lung 1 (2%) Fibrous Histiocytoma, Metastatic, Skeletal Muscle 1 (2%) Schwannoma Malignant 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (53) (53) (52) (52) (51) Adenoma 1 (2%) 1 (2%) Adrenal Medulla (52) (53) (52) (52) (51) Pheochromocytoma Benign 2 (4%) 1 (2%) 4 (8%) 1 (2%) Bilateral, Pheochromocytoma Benign 1 (2%) 1 (2%) Islets, Pancreatic (53) (53) (52) (52) (50) Adenoma 1 (2%) 1 (2%) Parathyroid Gland (45) (47) (46) (47) (46) Adenoma 1 (2%) Pituitary Gland (53) (53) (53) (52) (52) Carcinoma 1 (2%) Pars Distalis, Adenoma 22 (42%) 21 (40%) 17 (32%) 17 (33%) 1 (2%) Pars Distalis, Carcinoma 1 (2%) Pars Intermedia, Adenoma 2 (4%) Thyroid Gland (53) (53) (51) (52) (52) Bilateral, C-Cell, Adenoma 2 (4%) 4 (8%) 4 (8%) 3 (6%) C-Cell, Adenoma 8 (15%) 10 (19%) 12 (24%) 12 (23%) 7 (13%) C-Cell, Carcinoma 4 (8%) 1 (2%) 1 (2%) Follicular Cell, Adenoma 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ Page 3 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:51:53 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Clitoral Gland (53) (53) (53) (53) (50) Adenoma 1 (2%) Carcinoma 1 (2%) Ovary (53) (53) (52) (52) (49) Granulosa Cell Tumor Malignant 1 (2%) 1 (2%) Granulosa Cell Tumor Benign 1 (2%) Uterus (53) (53) (53) (52) (50) Adenoma 1 (2%) Carcinoma 1 (2%) Fibrosarcoma 1 (2%) Polyp Stromal 5 (9%) 7 (13%) 5 (9%) 6 (12%) 3 (6%) Polyp Stromal, Multiple 3 (6%) 2 (4%) Sarcoma 1 (2%) Sarcoma Stromal 1 (2%) Schwannoma Malignant 2 (4%) Schwannoma Malignant, Metastatic, Vagina 1 (2%) Squamous Cell Carcinoma 1 (2%) 1 (2%) 1 (2%) 2 (4%) Cervix, Granular Cell Tumor Benign 1 (2%) Cervix, Squamous Cell Carcinoma 2 (4%) Vagina (1) (1) (1) (1) Schwannoma Malignant 1 (100%) 1 (100%) Squamous Cell Carcinoma 1 (100%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (53) (53) (53) (53) (53) Lymph Node (4) (7) (2) (7) (14) Nephroblastoma, Metastatic, Kidney 1 (14%) Pancreatic, Nephroblastoma, Metastatic, Kidney 1 (14%) Lymph Node, Mandibular (53) (51) (52) (50) (51) Lymph Node, Mesenteric (53) (53) (52) (52) (49) Spleen (53) (53) (52) (52) (50) Thymus (53) (50) (48) (50) (51) Squamous Cell Carcinoma, Metastatic, Lung 1 (2%) ____________________________________________________________________________________________________________________________________ Page 4 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:51:53 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (53) (53) (52) (53) (52) Adenoma 2 (4%) 1 (2%) Carcinoma 6 (11%) 4 (8%) 2 (4%) 1 (2%) Carcinoma, Multiple 2 (4%) 1 (2%) 1 (2%) Fibroadenoma 27 (51%) 22 (42%) 25 (48%) 25 (47%) 11 (21%) Fibroadenoma, Multiple 13 (25%) 17 (32%) 15 (29%) 9 (17%) 1 (2%) Skin (53) (53) (53) (53) (53) Basal Cell Carcinoma 2 (4%) 1 (2%) Fibroma 2 (4%) 1 (2%) 3 (6%) 1 (2%) Fibrosarcoma 1 (2%) Fibrous Histiocytoma 1 (2%) Keratoacanthoma 1 (2%) Lipoma 1 (2%) 1 (2%) Liposarcoma 1 (2%) Sarcoma 1 (2%) 1 (2%) Schwannoma Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (53) (53) (53) (53) (53) Skeletal Muscle (1) (1) (1) (1) Fibrosarcoma, Metastatic, Lung 1 (100%) Fibrous Histiocytoma 1 (100%) Hemangiosarcoma 1 (100%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (53) (53) (53) (52) (52) Astrocytoma Malignant 1 (2%) Carcinoma, Metastatic, Pituitary Gland 1 (2%) 1 (2%) Granular Cell Tumor Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (53) (53) (52) (53) (52) Carcinoma, Metastatic, Mammary Gland 1 (2%) Cystic Keratinizing Epithelioma 1 (2%) 3 (6%) Cystic Keratinizing Epithelioma, Multiple 8 (15%) Fibrous Histiocytoma, Metastatic, Skeletal Page 5 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:51:53 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM - cont Muscle 1 (2%) Schwannoma Malignant, Metastatic, Skin 1 (2%) Squamous Cell Carcinoma 1 (2%) 1 (2%) Mediastinum, Fibrosarcoma 1 (2%) Nose (53) (53) (53) (53) (53) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Eye (53) (53) (53) (52) (52) Harderian Gland (53) (53) (53) (52) (52) Squamous Cell Carcinoma, Metastatic, Oral Mucosa 1 (2%) 3 (6%) Zymbal's Gland (1) (1) Adenoma 1 (100%) Carcinoma 1 (100%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (53) (53) (52) (52) (51) Nephroblastoma 1 (2%) 1 (2%) 1 (2%) Renal Tubule, Adenoma 1 (2%) Ureter (1) (1) (1) (1) Urinary Bladder (53) (53) (53) (52) (50) Nephroblastoma, Metastatic, Kidney 1 (2%) Papilloma 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(53) *(53) *(53) *(53) *(53) Lymphoma Malignant 1 (2%) 2 (4%) 2 (4%) 2 (4%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 6 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04 Route: GAVAGE Time: 09:51:53 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 51 49 50 50 46 Total Primary Neoplasms 110 106 110 126 121 Total Animals with Benign Neoplasms 49 43 48 46 36 Total Benign Neoplasms 92 85 96 93 73 Total Animals with Malignant Neoplasms 14 18 14 23 37 Total Malignant Neoplasms 18 21 14 33 48 Total Animals with Metastatic Neoplasms 3 5 3 3 Total Metastatic Neoplasm 4 8 6 3 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 7 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------